Jennifer Riggs

This inventor holds 20 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Cancer Treatment. Top assignee: Signal Pharmaceuticals, Inc.. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jennifer Riggs. Retrieved from https://idiyas.com/inventor/jennifer-riggs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 14.3

ph-index = 9

Forward Citations = 326(Granted Patents)

Company Filing History:

20 out of 169

Signal Pharmaceuticals, Inc.

patents

Years Active: 2011-2022

Loading Chart...

Areas of Expertise:

mTOR Kinase Inhibitors

Heteroaryl Compounds

Pyrrolopyrimidine

Cancer Treatment

Pyrazino[2,3-b]pyrazines

Oncology Indications

Compositions

Methods of Treatment

Synthesis

Purification

Substituted Compounds

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),

2. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),

3. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

4. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2017-10-24),

5. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),

6. 9623028 - Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof (2017-04-18),

7. 9428509 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-08-30),

8. 9346812 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-05-24),

9. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),

10. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),

11. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),

12. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),

13. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),

14. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2013-07-23),

15. 8383634 - Methods of treatment using heteroaryl compounds and compositions thereof (2013-02-26),

Title: The Innovative Contributions of Jennifer Riggs in Pharmaceutical Patents

Introduction: Jennifer Riggs, based in Cardiff, California, is a prominent inventor recognized for her significant contributions to the field of pharmaceuticals. With an impressive portfolio of 20 patents, she has made remarkable advancements in the area of mTOR kinase inhibitors, showcasing her expertise in medicinal chemistry and drug development.

Latest Patents: Among her latest patents is a development focused on substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors. This patent outlines methods for preparing compounds with specific heteroaryl structures. The innovations under her name illustrate her commitment to fighting diseases by inhibiting critical pathways involved in cell growth and proliferation. Additionally, her methodologies for synthesizing various substituted pyrazino[2,3-b]pyrazines further highlight her technical proficiency and inventive capabilities.

Career Highlights: Jennifer Riggs currently works at Signal Pharmaceuticals, Inc., a company known for its dedication to innovative healthcare solutions. Her role at Signal Pharmaceuticals has allowed her to collaborate on various projects aimed at developing new therapeutic agents. Her contributions extend beyond patents, as she plays a crucial role in advancing the company's research and development initiatives.

Collaborations: Throughout her career, Jennifer has worked alongside notable colleagues, including John J. Sapienza and Roy Leonard Harris, III. These collaborations foster a creative environment that encourages the exchange of ideas and leads to the development of groundbreaking inventions in the pharmaceutical industry.

Conclusion: Jennifer Riggs exemplifies the spirit of innovation through her extensive patent portfolio and her contributions to pharmaceutical research. Her work at Signal Pharmaceuticals, combined with her collaborative efforts, positions her as a key figure in the pursuit of new and effective medical treatments. As she continues to push the boundaries of scientific inquiry, her future endeavors are sure to create a lasting impact in the field of medicine.

Profile summary based on public USPTO records.